|Biotech Due Diligence||
Highlights from Spectrum Pharma $SPPI investor event (excerpts c/o SeekingAlpha) with updated commentary on every major development / commercial product. For archival purposes (June 2013)
The first part of my summary of news and notes from Spectrum Pharma's year-end earnings conference call focused on apaziquone, the bladder cancer drug that missed in phase 3 and was recently returned by partner Allergan. You can read SPPI Part 1 here.
Part 2 will cover other highlights, particularly regarding Fusilev and Zevalin. Of course all of these comments should be taken with a grain of salt given the bombshell press release SPPI released a couple weeks later. In some cases the change in commentary in such a short period of time is very difficult to reconcile.
For the moment, this will be the final installment of the BiotechDueDiligence AACR Annual Meeting preview..thanks for sticking with us. As always, see below for another collection of presentations from biotech companies covered on the website.
Preview Part 1 (SNTA, ASTX, NVS, INFI)
Preview Part 2
Preview Part 3 (ARRY, ASTX)
Preview Part 4 (ASTX, ARQL, BPAX)
Preview Part 5 (TKMR, EXEL, PCYC, IMMU, VRTX)
Preview Part 6 (CRIS INFI ISIS CLDX LGND PCYC)
Spectrum Pharma SPPI recently held their fourth-quarter and full-year 2012 earnings call. Topics of discussion included each of the marketed or late-stage cancer drugs: FUSILEV, ZEVALIN, FOLOTYN, belinostat, and apaziquone.
In this Part 1 post, I am including highlights from the SPPI and (former) partner Allergan AGN's earnings calls regarding apaziquone.
(continue reading full post for details)
TopoTarget (partner of Spectrum Pharma $SPPI) conference call notes - belinostat in CUP trial results
TopoTarget is a European biotech company that licensed the histone deacetylase (HDAC) inhibitor belinostat to Spectrum Pharma $SPPI. In June 2012 Topo released top-line data for the clinical trial in cancer of unknown primary (CUP) - belinostat failed to achieve the primary endpoint of an increase in progression-free survival (PFS). A secondary endpoint of objective response rate (ORR) was positive and statistically significant.
The company then held a conference call to explain the results and justify to shareholders why they shouldn't view this as a failure. They even went so far as to release a further press release in August 2012 with some new data-mining. This sort of behavior is typical of small biotech companies heavily reliant on the fate of a single drug, and diligent biotech investors must recognize this and not invest in a company advancing a drug out of necessity or convenience vs. actual clinical and commercial potential.
My notes from the conference call continue below the jump.
Your support is greatly appreciated